Ftc patent thicket humira 2023 biosimilar competition?

Here’s a concise view tying those elements together:

- What “patent thicket” means for Humira
- AbbVie built a large, overlapping patent portfolio around Humira (adalimumab), touching formulations, methods, manufacturing, and uses. Critics call this a patent thicket designed to delay biosimilar competition even after key patents expire.

- FTC and Humira (where things stood around 2023)
- The FTC has criticized pharma patent strategies (including pay-for-delay and dense patent thickets) as potentially anticompetitive. In past years the FTC pursued enforcement and investigations related to Humira’s strategy, aiming to curb practices that delay biosimilar entry.
- By 2023, the FTC’s public focus remained on these issues as part of broader antitrust scrutiny of pharma patent practices. The case status and outcomes have involved litigation activity rather than a single, simple ruling.

- Biosimilar competition to Humira in 2023
- 2023 marked the first real wave of U.S. biosimilar competition for Humira after many years of delay due to the patent portfolio and settlements.
- Entrants included Amgen’s Amjevita and other biosimilars from Boehringer Ingelheim/Samsung Bioepis and others. These launches began to erode Humira’s U.S. market share, with more entrants and price competition continuing into 2024.

- Takeaway
- 2023 was a pivotal year: real biosimilar competition to Humira began in earnest, while FTC scrutiny of patent-portfolio strategies and potential anticompetitive practices around Humira kept pressuring how these products enter and compete.
- The situation remains dynamic, with ongoing litigation, settlements, and regulatory scrutiny affecting timing and scope of biosimilar entry.

If you’d like, I can:
- Pull a precise timeline of 2023–2024 Humira biosimilar launches and dates.
- Summarize the specific FTC actions or filings related to Humira and patent thickets.
- Provide sources and brief legal/regulatory notes for deeper reading.

Would you prefer a quick timeline or a deeper legal/antitrust analysis?